Preloader Close
e q u i l i b r i o b i o s c i e n c e s
Dawnload One Pager

Why Equilibriobiosciences

Why EquilibrioBiosciences

Our Technology Differentiation

equilibriobiosciences
Choose 4

 

We are developing a novel biotherapeutic called SELTA, a first-in-class molecule with the unique ability to simultaneously modulate both immune cells and nerve cells to modify inflammatory disease and induce non-opioid analgesia.

SELTA is a TLR2/6 agonist derived from the normal microbial flora of a healthy
individual, suggesting the potential for limited off-target effects and
toxicity.

Downstream TLR2/6 signaling after SELTA leads to anti-inflammatory and analgesic effects.

Well-defined path to proof of concept:

  • Tailored drug formulation approaches to target the needs of specific disease
    populations.
  • Unique MOA, with preclinical data demonstrating potential clinical
    applications across multiple autoimmune and chronic inflammatory diseases.

Potential to be first-in-class molecule targeting TLR2/6 for auto-immune
diseases.

Summary

Why Invest in SELTA & EQUILIBRIO BIOSCIENCES?

Novel TLR2/6 agonist with dual mechanism of action to benefits patients with potentially quick acting and well tolerated new treatment option.

SELTA was isolated from a healthy individual, suggesting the potential for limited off-target effects and toxicity.

Compelling animal data in several inflammation models suggests the potential for development in multiple autoimmune diseases.

Exclusive license option from Northwestern University.

Leadership team of experienced translational research and biopharmaceutical professionals.

Psoriasis as a lead indication enables a risk-mitigated opportunity with an accessible patient population and well-established endpoints – efficiently achieve clinically meaningful milestones.

Leadership Team
team 1

Dr. Praveen Thumbikat, DVM

Founder & Chief Scientific Officer

Lou Pascarella, MBA

Chief Executive Officer
te

David Arvan

 Chief Business Officer